Shuji Ogino

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Bayesian analysis and risk assessment in genetic counseling and testing
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Mol Diagn 6:1-9. 2004
  2. pmc Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel with one or no detectable CFTR mutation
    S Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115 USA
    J Med Genet 41:e70. 2004
  3. ncbi request reprint Spinal muscular atrophy: molecular genetics and diagnostics
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Amory 3rd Floor, Boston, MA 02115, USA
    Expert Rev Mol Diagn 4:15-29. 2004
  4. ncbi request reprint Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Hum Genet 11:275-7. 2003
  5. ncbi request reprint Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Amory 3rd Floor, Boston, MA 02115, USA
    J Hum Genet 48:1-7. 2003
  6. ncbi request reprint Genetic testing and risk assessment for spinal muscular atrophy (SMA)
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Genet 111:477-500. 2002
  7. pmc Quantification of PCR bias caused by a single nucleotide polymorphism in SMN gene dosage analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Mol Diagn 4:185-90. 2002
  8. pmc Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:4591-8. 2009
  9. pmc Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial
    Shuji Ogino
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF Department of Pathology SO, Channing Division of Network Medicine, Department of Medicine DS, CSF, and Department of Surgery MMB, Brigham and Women s Hospital and Harvard Medical School, Boston, MA SO Department of Epidemiology SO, DS and Department of Biostatistics DS, Harvard School of Public Health, Boston, MA Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC DN Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital du Sacré Coeur de Montréal, Montreal, Canada RW Loyola University Stritch School of Medicine, Maywood, IL AH current Edward Cancer Center, Naperville, IL AH Northwestern University, Chicago, IL ABB Toledo Community Hospital Oncology Program, Toledo, OH RBM Division of Medical Oncology, Germany
    J Natl Cancer Inst 105:1789-98. 2013
  10. pmc Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mol Cancer 9:125. 2010

Detail Information

Publications113 found, 100 shown here

  1. pmc Bayesian analysis and risk assessment in genetic counseling and testing
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Mol Diagn 6:1-9. 2004
    ..We illustrate herein the application of Bayes' theorem and describe important basic principles in genetic risk assessment...
  2. pmc Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel with one or no detectable CFTR mutation
    S Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115 USA
    J Med Genet 41:e70. 2004
  3. ncbi request reprint Spinal muscular atrophy: molecular genetics and diagnostics
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Amory 3rd Floor, Boston, MA 02115, USA
    Expert Rev Mol Diagn 4:15-29. 2004
    ..New technologies, such as monosomal analysis techniques, may be widely available in the future...
  4. ncbi request reprint Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Hum Genet 11:275-7. 2003
    ..In conclusion, our data provide evidence that gene conversion from SMN2 to SMN1 occurs, and that SMN1 converted from SMN2 is present in the general population...
  5. ncbi request reprint Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Amory 3rd Floor, Boston, MA 02115, USA
    J Hum Genet 48:1-7. 2003
    ..Further studies on both SNPs are needed to determine their exact role in various clinical settings...
  6. ncbi request reprint Genetic testing and risk assessment for spinal muscular atrophy (SMA)
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Genet 111:477-500. 2002
    ..New technologies, such as haploid analysis techniques, may be widely available in the future...
  7. pmc Quantification of PCR bias caused by a single nucleotide polymorphism in SMN gene dosage analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Mol Diagn 4:185-90. 2002
    ..As additional clinically significant single nucleotide polymorphisms (SNPs) are discovered, assessment of PCR bias, and judicious selection of standards and controls, will be increasingly important for quantitative PCR assays...
  8. pmc Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:4591-8. 2009
    ..However, it is unclear whether 18q LOH in colorectal cancer has any prognostic implication independent of MSI status and other potential predictors of clinical outcome...
  9. pmc Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial
    Shuji Ogino
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF Department of Pathology SO, Channing Division of Network Medicine, Department of Medicine DS, CSF, and Department of Surgery MMB, Brigham and Women s Hospital and Harvard Medical School, Boston, MA SO Department of Epidemiology SO, DS and Department of Biostatistics DS, Harvard School of Public Health, Boston, MA Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC DN Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital du Sacré Coeur de Montréal, Montreal, Canada RW Loyola University Stritch School of Medicine, Maywood, IL AH current Edward Cancer Center, Naperville, IL AH Northwestern University, Chicago, IL ABB Toledo Community Hospital Oncology Program, Toledo, OH RBM Division of Medical Oncology, Germany
    J Natl Cancer Inst 105:1789-98. 2013
    ..Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer...
  10. pmc Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mol Cancer 9:125. 2010
    ..Thus, it is of particular interest to examine whether its wide variation can be attributed to clinical, pathologic or molecular features...
  11. pmc A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 137:1609-20.e1-3. 2009
    ..Synchronous colon cancers have not been compared with control solitary cancers in a prospective study...
  12. pmc CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival
    Ron Firestein
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Int J Cancer 126:2863-73. 2010
    ..These data support a potential link between CDK8 and beta-catenin, and suggest that CDK8 may identify a subset of colon cancer patients with a poor prognosis...
  13. pmc PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 10:534-41. 2008
    ..In addition, Pyrosequencing is useful in detecting PIK3CA mutation in archival paraffin tumor tissue. PIK3CA mutational data further emphasize heterogeneity of colorectal cancer at the molecular level...
  14. pmc Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009
    ..Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR...
  15. pmc DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:3663-71. 2009
    ..We hypothesized that cellular DNMT3B level might influence the occurrence of widespread CpG island methylation (i.e., the CpG island methylator phenotype, CIMP) in colon cancer...
  16. pmc SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mod Pathol 22:922-32. 2009
    ..In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype...
  17. pmc Tumor TP53 expression status, body mass index and prognosis in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Medicine Brigham and Women s Hospital, Boston, MA 02215, USA
    Int J Cancer 131:1169-78. 2012
    ..These molecular pathological epidemiology data may support a dual role of TP53 alterations in cell-cycle deregulation and cell autonomy with respect to energy balance status...
  18. pmc PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:1477-84. 2009
    ..PIK3CA mutation and subsequent activation of the AKT pathway play an important role in colorectal carcinogenesis. However, little is known about the prognostic role of PIK3CA mutation in colon cancer...
  19. doi request reprint CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Mod Pathol 21:245-55. 2008
    ..Our data may provide supporting evidence for a difference in pathogenesis of DNA methylation between CIMP-low and CIMP-high tumors...
  20. pmc Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer
    Aditi Hazra
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Causes Control 21:331-45. 2010
    ..Collectively, these exploratory data provide suggestive evidence for the association of MTHFR 429 Ala/ Ala and TCN2 259 Arg/Arg and CIMP status in colorectal cancer...
  21. pmc Aurora-A expression is independently associated with chromosomal instability in colorectal cancer
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 11:418-25. 2009
    ..In conclusion, AURKA overexpression is independently associated with CIN in colorectal cancer, supporting a potential role of Aurora kinase-A in colorectal carcinogenesis through genomic instability (rather than epigenomic instability)...
  22. pmc Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    PLoS ONE 3:e3698. 2008
    ..In stratified analyses, the relations of CIMP-high with poor differentiation, KRAS mutation and LINE-1 hypomethylation significantly differed according to MSI status...
  23. pmc Prediagnostic body mass index and pancreatic cancer survival
    Chen Yuan
    Chen Yuan, Shuji Ogino, Kimmie Ng, Zhi Rong Qian, Douglas A Rubinson, and Brian M Wolpin, Dana Farber Cancer Institute Ying Bao, Shuji Ogino, Kimmie Ng, Meir J Stampfer, Edward L Giovannucci, and Brian M Wolpin, Brigham and Women s Hospital, Harvard Medical School and Chen Wu, Peter Kraft, Shuji Ogino, Meir J Stampfer, and Edward L Giovannucci, Harvard School of Public Health, Boston, MA
    J Clin Oncol 31:4229-34. 2013
    ..Although obesity is associated with increased incidence of pancreatic cancer, studies have not prospectively evaluated prediagnostic body mass index (BMI) and survival...
  24. pmc Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers
    Yu Imamura
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Room JF 215C, Boston, MA 02215, USA
    Clin Cancer Res 18:4753-63. 2012
    ..Cox proportional hazards model was used to compute mortality HR, adjusting for potential confounders, including stage, PIK3CA mutations, microsatellite instability, CpG island methylator phenotype, and LINE-1 methylation...
  25. pmc Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:890-900. 2012
    ..irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status...
  26. pmc IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 9:1091-8. 2007
    ..Our data suggest complex relationship between global genomic/epigenomic phenomena (such as MSI/CIMP), single molecular events (e.g., IGFBP3 methylation, TP53 mutation, and TGFBR2 mutation), and the related pathways...
  27. pmc Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 105:420-33. 2010
    ....
  28. ncbi request reprint WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Takako Kawasaki
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Mod Pathol 21:150-8. 2008
    ..Our data suggest a possible role of WRN methylation in mucinous differentiation, and may provide explanation to the enigmatic association between mucin and MSI/CIMP...
  29. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  30. pmc CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 USA
    Gut 58:90-6. 2009
    ..The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain...
  31. pmc NRAS mutations are rare in colorectal cancer
    Natsumi Irahara
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Diagn Mol Pathol 19:157-63. 2010
    ..NRAS mutations were detected in 5 (2.2%) of the 225 colorectal cancers and tended to occur in left-sided cancers arising in women, but did not seem to be associated with any of the molecular features that were examined...
  32. pmc Cohort study of fatty acid synthase expression and patient survival in colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:5713-20. 2008
    ..Fatty acid synthase (FASN) is physiologically regulated by energy balance and is often upregulated in colorectal cancer. Nonetheless, the influence of FASN expression on patient outcome is uncertain...
  33. pmc MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Causes Control 22:301-9. 2011
    ..MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain...
  34. ncbi request reprint MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Carcinogenesis 28:1985-90. 2007
    ..56C>T) of the MGMT promoter and promoter methylation/silencing of MGMT in colorectal cancer. Our data provide compelling evidence for common susceptibility for MGMT promoter CpG island methylation...
  35. pmc JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 11:87-95. 2009
    ..JCVT was unrelated with patient survival. In conclusion, JCVT expression in colorectal cancer is independently associated with p53 expression and CIN, which may lead to uncontrolled cell proliferation...
  36. pmc Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
    JAMA 305:1685-94. 2011
    ..Alterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases...
  37. pmc Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations
    Hongmei Nan
    Affiliations of authors Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD HN Channing Division of Network Medicine, Department of Medicine HN, DJH, ELG, CSF, ATC and Department of Epidemiology DJH, PK, ELG, SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Center for Molecular Oncologic Pathology TM, YI, AK, MY, SO, Department of Medical Oncology TM, MS, YI, AK, MY, CSF, SO, MLF, and Department of Biostatistics and Computational Biology LW, Dana Farber Cancer Institute, Boston, MA Department of Epidemiology DJH, ELG, SO and Department of Nutrition, Harvard School of Public Health, Boston, Simancas 47130
    J Natl Cancer Inst 105:1852-61. 2013
    ....
  38. pmc Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer
    Mai Yamauchi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 22:1142-52. 2013
    ....
  39. pmc Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1151-6. 2013
    ..No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification...
  40. pmc Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1027-35. 2013
    ..Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic β-cell dysfunction...
  41. pmc Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Rm JF 215C, Boston, MA 02215, USA
    J Natl Cancer Inst 105:130-40. 2013
    ..We tested the hypothesis that CRC family history might confer a higher risk of LINE-1 methylation-low CRC...
  42. pmc Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 367:1596-606. 2012
    ....
  43. pmc Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
    Arch Surg 147:715-23. 2012
    ..To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons...
  44. pmc A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 100:1734-8. 2008
    ..In conclusion, tumoral LINE-1 hypomethylation is independently associated with shorter survival among colon cancer patients...
  45. ncbi request reprint TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:614-20. 2007
    ....
  46. pmc Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells
    Natsumi Irahara
    Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115, USA
    J Mol Diagn 12:177-83. 2010
    ..9) in leukocyte DNA. In conclusion, bisulfite conversion and PCR-pyrosequencing assay can measure LINE-1 methylation in macrodissected colon cancer, normal colon, and blood DNA, and may be useful in clinical and research settings...
  47. pmc Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 103:1540-51. 2011
    ..Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown...
  48. pmc HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Am J Pathol 176:2292-301. 2010
    ..039). In conclusion, HIF1A expression is independently associated with poor prognosis in colorectal cancer, suggesting HIF1A as a biomarker with potentially important therapeutic implications...
  49. pmc CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Mol Diagn 8:582-8. 2006
    ..In conclusion, CIMP-low colorectal cancer is associated with male sex and KRAS mutations. The hypothesis that CIMP-low tumors are different from CIMP-high and CIMP-0 tumors needs to be tested further...
  50. pmc A cohort study of p27 localization in colon cancer, body mass index, and patient survival
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital, Boston, and Harvard Medical School 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1849-58. 2009
    ..08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction...
  51. ncbi request reprint A Prospective Study of Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) and Risk of Colorectal Cancer
    Raaj S Mehta
    Affiliations of authors Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA RSM, ATC Gastrointestinal Research Group, Institute of Medical Sciences, Aberdeen University, Aberdeen, United Kingdom NB Department of Epidemiology XG, SO, ELG and Department of Nutrition MS, KW, XG, ELG, Harvard School of Public Health, Boston, MA Department of Pathology, University of Tokyo, Tokyo, Japan TM Channing Division of Network Medicine, Department of Medicine CSF, ELG, ATC and Department of Pathology SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA CSF, SO
    J Natl Cancer Inst 106:dju016. 2014
    ..Chronic inflammation plays a role in the development of colorectal cancer (CRC). The novel plasma inflammatory biomarker macrophage inhibitory cytokine-1 (MIC-1, GDF15) may have a direct mechanistic role in colorectal carcinogenesis...
  52. pmc Aspirin use and risk of colorectal cancer according to BRAF mutation status
    Reiko Nishihara
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    JAMA 309:2563-71. 2013
    ....
  53. pmc Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:2257-68. 2012
    ..Thus, we hypothesized that PIK3CA exon 9 and exon 20 mutations might have differential effects on clinical outcome in colorectal cancer, and that concomitant PIK3CA exon 9 and 20 mutations might confer aggressive tumor behavior...
  54. pmc Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 19:1944-53. 2012
    ..However, little is known about the prognostic significance of tumor growth pattern, independent of tumoral molecular alterations and other histologic features...
  55. ncbi request reprint Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 19:1083-90. 2006
    ..KRAS mutations were not concordant in any synchronous neoplasia pair. In conclusion, epigenetic alterations at CIMP-specific promoter CpG islands in synchronous colorectal neoplasias likely have both random and nonrandom components...
  56. pmc Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer
    Noriko Tanaka
    Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
    Am J Pathol 177:2731-40. 2010
    ..Our novel data suggest two distinct perturbations, resulting in differential locus-specific propensity of CpG methylation...
  57. pmc Interaction of molecular markers and physical activity on mortality in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5931-6. 2009
    ..Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown...
  58. pmc Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Gastroenterology 136:1242-50. 2009
    ..There is controversy over the pro-oncogenic or antioncogenic effects of PPARG, and little is known about its prognostic significance in colon cancer...
  59. pmc Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
    Mai Yamauchi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Gut 61:847-54. 2012
    ..Considering a possible role of bowel contents (including microbiome) in carcinogenesis, this study hypothesised that tumour molecular features might gradually change along bowel subsites, rather than change abruptly at splenic flexure...
  60. pmc Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study
    Aya Kuchiba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 104:415-20. 2012
    ..9 and 7.1, respectively, per 100,000 person-years. This molecular pathological epidemiology study supports a role of energy metabolism in colorectal cancer pathogenesis...
  61. ncbi request reprint Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Mod Pathol 20:15-22. 2007
    ..These associations are stronger among p53 wild-type tumors, implying important interplay of p27 and p53 functions (or dysfunctions) in the development of various molecular subtypes of colorectal cancer...
  62. pmc Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 139:1855-64. 2010
    ..IGF2 LOI correlates with hypomethylation at the differentially methylated region (DMR)-0. An assay for methylation of the DMR0 could overcome the limitations of the conventional IGF2 LOI assay...
  63. pmc STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1452-62. 2011
    ..Although the STAT3 signaling pathway is a potential drug target, clinical, pathologic, molecular, or prognostic features of STAT3-activated colorectal cancer remain uncertain...
  64. pmc Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4665-73. 2009
    ....
  65. pmc A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis
    Shuji Ogino
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney St, Room JF 215C, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 104:2047-56. 2009
    ..STMN1 activity is influenced by p53, p27, and the PI3K/AKT pathway. However, its prognostic significance in colon cancer is uncertain...
  66. pmc Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 9:569-77. 2007
    ..Cytoplasmic beta-catenin is associated with COX-2 overexpression, supporting the role of cytoplasmic beta-catenin in stabilizing PTGS2 (COX-2) mRNA...
  67. pmc Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Mol Diagn 9:305-14. 2007
    ..In conclusion, a panel of markers including at least RUNX3, CACNA1G, IGF2, and MLH1 can serve as a sensitive and specific marker panel for CIMP-high...
  68. ncbi request reprint Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 30:1175-83. 2006
    ..Both MSI and CIMP appear to play a role in the pathogenesis of specific morphologic patterns of colorectal carcinoma...
  69. pmc Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:585-92. 2007
    ....
  70. ncbi request reprint Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:842-9. 2007
    ..Fatty acid synthase overexpression was not significantly correlated with sex, tumor location, p53, or KRAS/BRAF status. In conclusion, FASN overexpression in colorectal cancer is associated with MSI-H, independent of CIMP status...
  71. pmc Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    BMC Cancer 8:33. 2008
    ..Therefore, we hypothesized that COX-2 may play a less important role in the serrated pathway...
  72. pmc Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 15:6412-20. 2009
    ....
  73. pmc LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Cancer 122:2767-73. 2008
    ..Our data also support a possible link between global hypomethylation and chromosomal instability...
  74. pmc Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Pathol 222:350-66. 2010
    ..Our data offer a possible mechanism by which MSI confers an improved clinical outcome and support efforts to augment the host immune response in the tumour microenvironment as a strategy of targeted immunotherapy...
  75. pmc PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype
    Yoshifumi Baba
    Department of Medical Oncology, Dana FarberCancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:822-31. 2010
    ..However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain...
  76. pmc Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer
    Eva S Schernhammer
    Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
    Gut 59:794-9. 2010
    ..Long interspersed nucleotide element-1 (LINE-1) is an emerging indicator of genome-wide DNA methylation level that has previously been linked to colon cancer survival...
  77. pmc Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 75 Francis St, BWH Pathology, Boston, MA 02115, USA
    Gut 56:1564-71. 2007
    ..O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low)...
  78. pmc Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:8221-7. 2008
    ..However, previous data on the influence of COX-2 expression on patient outcome have been conflicting...
  79. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  80. pmc The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer
    Do Youn Park
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Am J Pathol 171:1509-19. 2007
    ..Loss of Cables expression in 65% of CRCs suggests that it is a common event in colonic carcinogenesis, with promoter methylation and LOH appearing to be important mechanisms of Cables gene inactivation...
  81. ncbi request reprint Comparison of PCR-RFLP with allele-specific PCR in genetic testing for spinal muscular atrophy
    Ruliang Xu
    Department of Pathology, Harvard Medical School, and Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Genet Test 7:277-81. 2003
    ..Our data indicate that PCR-RFLP can be used for most diagnostic purposes, whereas the use of allelespecific PCR may be considered with caution under certain circumstances...
  82. ncbi request reprint Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Genet Med 6:439-49. 2004
    ..Our methods are particularly useful for calculating the CF disease risk for a fetus with echogenic bowel. In genetics practice, however, there are other scenarios for which our previous methods are inadequate...
  83. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  84. pmc KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7322-9. 2009
    ....
  85. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..Whether these results apply to other cancer types is unknown but worthy of further study...
  86. pmc Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Cancer Epidemiol Biomarkers Prev 19:2777-85. 2010
    ..Proteases play a critical role in tumorigenesis and are upregulated in colorectal cancer and neoplastic polyps. In animal models, cathepsin B (CTSB)-activatable imaging agents show high enzyme activity within intestinal tumors...
  87. ncbi request reprint Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests
    Shuji Ogino
    Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genet Med 7:317-27. 2005
    ..Although neonatal screening (or newborn screening) for cystic fibrosis (CF) is commonly practiced, systematic methods for accurate risk calculations are currently lacking...
  88. ncbi request reprint Aspirin and the risk of colorectal cancer in relation to the expression of COX-2
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 356:2131-42. 2007
    ..Regular use of aspirin reduces the risk of a colorectal neoplasm, but the mechanism by which aspirin affects carcinogenesis in the colon is not well understood...
  89. ncbi request reprint New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Hum Genet 12:1015-23. 2004
    ..Our data also suggest selection of the 1-1 haplotype and the presence of rare chromosomes with three copies of SMN1...
  90. pmc Aspirin use and survival after diagnosis of colorectal cancer
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, GRJ 722 Boston, MA 02114, USA
    JAMA 302:649-58. 2009
    ..Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown...
  91. pmc CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity
    Ron Firestein
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 455:547-51. 2008
    ..Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in beta-catenin-driven malignancies...
  92. ncbi request reprint Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Genet Couns 16:29-39. 2007
    ..Our methods can be applied to many different scenarios, including those where the sensitivity of genetic testing varies for different family members at risk...
  93. pmc Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 8:458-64. 2006
    ..Our data suggest that a combined analysis of COX-2 and p53 may be more useful for the molecular classification of colorectal cancer than either COX-2 or p53 analysis alone...
  94. pmc Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Mol Diagn 8:209-17. 2006
    ..In conclusion, sodium bisulfite conversion and quantitative MethyLight assays have good precision and linearity and can be effectively used for high-throughput DNA methylation analysis on paraffin-embedded tissue...
  95. pmc A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status
    Eva S Schernhammer
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:2895-8. 2008
    ..In conclusion, the influence of dietary one-carbon nutrient intake on colon cancer risk does not seem to differ according to MSI or KRAS mutational status...
  96. pmc Molecular classification and correlates in colorectal cancer
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Mol Diagn 10:13-27. 2008
    ....
  97. pmc 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    BMC Cancer 7:72. 2007
    ..However, no study has examined 18q LOH in relation to CIMP-high, CIMP-low (less extensive promoter methylation) and CIMP-0 (CIMP-negative), determined by quantitative DNA methylation analysis...
  98. pmc p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2513-21. 2009
    ..Patient BMI also differentially influences prognosis according to p21 CDKN1A status. Our data suggest host-tumor interactions influencing tumor aggressiveness...
  99. pmc Physical activity and male colorectal cancer survival
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Arch Intern Med 169:2102-8. 2009
    ..Although physically active individuals have a lower risk of developing colorectal cancer, few studies have examined whether exercise benefits colorectal cancer survivors...
  100. ncbi request reprint The practice of science at its best
    Shuji Ogino
    Fertil Steril 80:228-9; author reply 229. 2003
  101. ncbi request reprint Genetic risk assessment in carrier testing for spinal muscular atrophy
    Shuji Ogino
    Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Am J Med Genet 110:301-7. 2002
    ..We present updated calculations for disease and non-disease allele frequencies and we describe how these frequencies can be used for genetic risk assessment in carrier testing for SMA...